JP Morgan Chase
JAZZ icon

JP Morgan Chase’s Jazz Pharmaceuticals JAZZ Stock Holding History

JP Morgan Chase’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-68,700
Closed -$8.45M – 7641
2023
Q4 		$8.45M Buy
+68,700
New +$8.57M ﹤0.01% 2633
2021
Q2 		– Sell
-44,800
Closed -$7.36M – 6463
2021
Q1 		$7.36M Sell
44,800
-50,000
-53% -$8.23M ﹤0.01% 2633
2020
Q4 		$15.6M Buy
94,800
+21,700
+30% +$3.23M ﹤0.01% 1825
2020
Q3 		$10.2M Buy
+73,100
New +$9.06M ﹤0.01% 2024
2018
Q3 		– Sell
-120,000
Closed -$20.7M – 5735
2018
Q2 		$20.7M Buy
120,000
+80,000
+200% +$13.1M ﹤0.01% 1551
2018
Q1 		$6.04M Buy
+40,000
New +$5.87M ﹤0.01% 2412
2017
Q4 		– Sell
-30,000
Closed -$4.44M – 5504
2017
Q3 		$4.44M Buy
+30,000
New +$4.54M ﹤0.01% 2645
2017
Q2 		– Sell
-27,000
Closed -$3.92M – 5082
2017
Q1 		$3.92M Buy
+27,000
New +$3.52M ﹤0.01% 2607
2016
Q3 		– Sell
-226,300
Closed -$32M – 4671
2016
Q2 		$32M Buy
+226,300
New +$33.4M 0.01% 1071

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

JP Morgan Chase's JAZZ Position: Q2 2026 in Review

JP Morgan Chase reduced its Jazz Pharmaceuticals (JAZZ) stake by 3.6% in Q2 2026, selling an estimated $9.54M and leaving 1,160,786 shares worth $277M. The position accounts for 0.02% of the portfolio, ranked #638.

JP Morgan Chase first reported a position in JAZZ in Q2 2013 and has held it in 53 quarters since. The position peaked at $527M in Q2 2022. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • JP Morgan Chase held 1,160,786 shares of Jazz Pharmaceuticals worth $277M as of Q2 2026.
  • JP Morgan Chase sold 43,567 Jazz Pharmaceuticals shares in Q2 2026, an estimated $9.54M.
  • Jazz Pharmaceuticals made up 0.02% of JP Morgan Chase's portfolio in Q2 2026, its #638 holding.
  • JP Morgan Chase first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • JP Morgan Chase's Jazz Pharmaceuticals position peaked at $527M in Q2 2022.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.